Heat Biologics, Inc. (NASDAQ:HTBX) Files An 8-K Other Events
Item 8.01 Other Information
On June 22, 2020, Heat Biologics, Inc. (the Company) issued a press release announcing that its Pelican Therapeutics subsidiary (Pelican) has dosed the first patient in its Phase 1 clinical trial of Pelicans PTX-35 monoclonal antibody. This trial is supported by a $15.2 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT).
Item 9.01 Financial Statements and Exhibits.
The following exhibit is filed with this Current Report on Form 8-K.
HEAT BIOLOGICS, INC. Exhibit
EX-99.1 2 htbx_ex99z1.htm PRESS RELEASE Press Release EXHIBIT 99.1 Heat Biologics Announces First Patient Treated in First-in-Human Clinical Trial of PTX-35 Durham,…
To view the full exhibit click
About Heat Biologics, Inc. (NASDAQ:HTBX)
Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.